Cargando…

Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment

While protein aggregation is predominantly associated with loss of function and toxicity, it is also known to increase survival of bacteria under stressful conditions. Indeed, protein aggregation not only helps bacteria to cope with proteotoxic stresses like heat shocks or oxidative stress, but a gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bollen, Celien, Dewachter, Liselot, Michiels, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085434/
https://www.ncbi.nlm.nih.gov/pubmed/33937340
http://dx.doi.org/10.3389/fmolb.2021.669664
_version_ 1783686339509616640
author Bollen, Celien
Dewachter, Liselot
Michiels, Jan
author_facet Bollen, Celien
Dewachter, Liselot
Michiels, Jan
author_sort Bollen, Celien
collection PubMed
description While protein aggregation is predominantly associated with loss of function and toxicity, it is also known to increase survival of bacteria under stressful conditions. Indeed, protein aggregation not only helps bacteria to cope with proteotoxic stresses like heat shocks or oxidative stress, but a growing number of studies suggest that it also improves survival during antibiotic treatment by inducing dormancy. A well-known example of dormant cells are persisters, which are transiently refractory to the action of antibiotics. These persister cells can switch back to the susceptible state and resume growth in the absence of antibiotics, and are therefore considered an important cause of recurrence of infections. Mounting evidence now suggests that this antibiotic-tolerant persister state is tightly linked to—or perhaps even driven by—protein aggregation. Moreover, another dormant bacterial phenotype, the viable but non-culturable (VBNC) state, was also shown to be associated with aggregation. These results indicate that persisters and VBNC cells may constitute different stages of the same dormancy program induced by progressive protein aggregation. In this mini review, we discuss the relation between aggregation and bacterial dormancy, focusing on both persisters and VBNC cells. Understanding the link between protein aggregation and dormancy will not only provide insight into the fundamentals of bacterial survival, but could prove highly valuable in our future battle to fight them.
format Online
Article
Text
id pubmed-8085434
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80854342021-05-01 Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment Bollen, Celien Dewachter, Liselot Michiels, Jan Front Mol Biosci Molecular Biosciences While protein aggregation is predominantly associated with loss of function and toxicity, it is also known to increase survival of bacteria under stressful conditions. Indeed, protein aggregation not only helps bacteria to cope with proteotoxic stresses like heat shocks or oxidative stress, but a growing number of studies suggest that it also improves survival during antibiotic treatment by inducing dormancy. A well-known example of dormant cells are persisters, which are transiently refractory to the action of antibiotics. These persister cells can switch back to the susceptible state and resume growth in the absence of antibiotics, and are therefore considered an important cause of recurrence of infections. Mounting evidence now suggests that this antibiotic-tolerant persister state is tightly linked to—or perhaps even driven by—protein aggregation. Moreover, another dormant bacterial phenotype, the viable but non-culturable (VBNC) state, was also shown to be associated with aggregation. These results indicate that persisters and VBNC cells may constitute different stages of the same dormancy program induced by progressive protein aggregation. In this mini review, we discuss the relation between aggregation and bacterial dormancy, focusing on both persisters and VBNC cells. Understanding the link between protein aggregation and dormancy will not only provide insight into the fundamentals of bacterial survival, but could prove highly valuable in our future battle to fight them. Frontiers Media S.A. 2021-04-16 /pmc/articles/PMC8085434/ /pubmed/33937340 http://dx.doi.org/10.3389/fmolb.2021.669664 Text en Copyright © 2021 Bollen, Dewachter and Michiels. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Bollen, Celien
Dewachter, Liselot
Michiels, Jan
Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment
title Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment
title_full Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment
title_fullStr Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment
title_full_unstemmed Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment
title_short Protein Aggregation as a Bacterial Strategy to Survive Antibiotic Treatment
title_sort protein aggregation as a bacterial strategy to survive antibiotic treatment
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085434/
https://www.ncbi.nlm.nih.gov/pubmed/33937340
http://dx.doi.org/10.3389/fmolb.2021.669664
work_keys_str_mv AT bollencelien proteinaggregationasabacterialstrategytosurviveantibiotictreatment
AT dewachterliselot proteinaggregationasabacterialstrategytosurviveantibiotictreatment
AT michielsjan proteinaggregationasabacterialstrategytosurviveantibiotictreatment